Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USAWOS
International journal of chronic obstructive pulmonary disease, Volume 132018, Pages 2969-2984.
Keywords:COPDbronchodilatorco-suspension delivery technologymuscarinic antagonistβ2-agonist
These results demonstrated the efficacy of GFF MDI in patients with moderate-to-very severe COPD. GFF MDI was well tolerated, with a safety profile commensurate with long-acting bronchodilators.